
Xiao-tian Zhang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/128164/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial. Journal of Cancer Research and Clinical Oncology, 2023, 149, 779-789.	2.5	10
2	PTCH1 mutation promotes antitumor immunity and the response to immune checkpoint inhibitors in colorectal cancer patients. Cancer Immunology, Immunotherapy, 2022, 71, 111-120.	4.2	11
3	Serum Biomarker Status with a Distinctive Pattern in Prognosis of Gastroenteropancreatic Neuroendocrine Carcinoma. Neuroendocrinology, 2022, 112, 733-743.	2.5	3
4	Alterations in DNA damage response and repair genes as potential biomarkers for immune checkpoint blockade in gastrointestinal cancer. Cancer Biology and Medicine, 2022, 19, 1139-1149.	3.0	4
5	miRNAs derived from plasma small extracellular vesicles predict organo-tropic metastasis of gastric cancer. Gastric Cancer, 2022, 25, 360.	5.3	9
6	Plasma extracellular vesicle derived protein profile predicting and monitoring immunotherapeutic outcomes of gastric cancer. Journal of Extracellular Vesicles, 2022, 11, e12209.	12.2	18
7	Characteristics and Prognosis of Acquired Resistance to Immune Checkpoint Inhibitors in Gastrointestinal Cancer. JAMA Network Open, 2022, 5, e224637.	5.9	6
8	Establishment of prognostic models for adenocarcinoma of oesophagogastric junction patients with neoadjuvant chemoradiotherapy: a real-world study. Radiation Oncology, 2022, 17, 45.	2.7	7
9	Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment. BMC Cancer, 2022, 22, 355.	2.6	2
10	Evaluation of Event-Free Survival Surrogating Overall Survival as the Endpoint in Neoadjuvant Clinical Trials of Gastroesophageal Adenocarcinoma. Frontiers in Oncology, 2022, 12, 835389.	2.8	2
11	Mutations of PI3K-AKT-mTOR pathway as predictors for immune cell infiltration and immunotherapy efficacy in dMMR/MSI-H gastric adenocarcinoma. BMC Medicine, 2022, 20, 133.	5.5	27
12	Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nature Medicine, 2022, 28, 1189-1198.	30.7	190
13	Prognostic and predictive impact of circulating tumor DNA in advanced gastric cancer treated with immune checkpoint blockade Journal of Clinical Oncology, 2022, 40, e16019-e16019.	1.6	0
14	Genomic characterization of Chinese locally advanced or metastatic gastric cancer Journal of Clinical Oncology, 2022, 40, e16085-e16085.	1.6	0
15	Safety, tolerability, and preliminary efficacy results in patients with advanced gastric/gastroesophageal junction adenocarcinoma from a phase lb/II study of CLDN18.2 CAR T-cell therapy (CT041) Journal of Clinical Oncology, 2022, 40, 4017-4017.	1.6	2
16	Abstract 5129: Clinical implication of plasma ctDNA features in HER2-positive gastric cancer treated with combinations of trastuzumab & amp; anti-PD-1 agents. Cancer Research, 2022, 82, 5129-5129.	0.9	0
17	FAT4 mutation as a potential predictive biomarker for immunotherapy combined with anti-angiogenic therapy in MSS metastatic colorectal cancer Journal of Clinical Oncology, 2022, 40, e15504-e15504.	1.6	1
18	ChosenHRDw: A novel tool for the detection of homologous recombination deficiency(HRD) using low-pass whole-genome sequencing Journal of Clinical Oncology, 2022, 40, e17573-e17573.	1.6	0

#	Article	IF	CITATIONS
19	Impact of 68Ga-NOTA-MAL-MZHER2 PET imaging in advanced gastric cancer patients and therapeutic response monitoring. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 161-175.	6.4	19
20	Ultrasensitive Gastric Cancer Circulating Tumor Cellular <i>CLDN18.2</i> RNA Detection Based on a Molecular Beacon. Analytical Chemistry, 2021, 93, 665-670.	6.5	22
21	Early change in peripheral CD4 ⁺ T cells associated with clinical outcomes of immunotherapy in gastrointestinal cancer. Immunotherapy, 2021, 13, 55-66.	2.0	15
22	Response to the rechallenge of combination immunotherapy in a patient with late-stage gastric cancer: case report. Annals of Palliative Medicine, 2021, .	1.2	2
23	Phase I study of intraperitoneal bevacizumab for treating refractory malignant ascites. Journal of International Medical Research, 2021, 49, 030006052098666.	1.0	4
24	Early Interdisciplinary Supportive Care in Patients With Previously Untreated Metastatic Esophagogastric Cancer: A Phase III Randomized Controlled Trial. Journal of Clinical Oncology, 2021, 39, 748-756.	1.6	63
25	Germline HLA-B evolutionary divergence to influence efficacy of immune checkpoint blockade therapy in gastrointestinal cancer Journal of Clinical Oncology, 2021, 39, e16101-e16101.	1.6	0
26	A genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer. Npj Precision Oncology, 2021, 5, 36.	5.4	20
27	Phase I study of the recombinant humanized anti-HER2 monoclonal antibody–MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors. Gastric Cancer, 2021, 24, 913-925.	5.3	61
28	A multicenter study assessing the prevalence of germline genetic alterations in Chinese gastric-cancer patients. Gastroenterology Report, 2021, 9, 339-349.	1.3	4
29	Clinicopathological features and lymph node and distant metastasis patterns in patients with gastroenteropancreatic mixed neuroendocrineâ€nonâ€neuroendocrine neoplasm. Cancer Medicine, 2021, 10, 4855-4863.	2.8	10
30	Association of Lymphocyte-to-Monocyte Ratio With Survival in Advanced Gastric Cancer Patients Treated With Immune Checkpoint Inhibitor. Frontiers in Oncology, 2021, 11, 589022.	2.8	20
31	The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. Cancer Communications, 2021, 41, 747-795.	9.2	323
32	Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncology, The, 2021, 22, 1081-1092.	10.7	178
33	Reply to M. A. Liu et al. Journal of Clinical Oncology, 2021, 39, 2519-2519.	1.6	0
34	The Inconsistent and Inadequate Reporting of Immune-Related Adverse Events in PD-1/PD-L1 Inhibitors: A Systematic Review of Randomized Controlled Clinical Trials. Oncologist, 2021, 26, e2239-e2246.	3.7	6
35	Clinicopathological Characteristics and Response to Chemotherapy in Treatment-Naive Epstein–Barr Virus Associated Gastric Cancer: A Retrospective Study. Frontiers in Oncology, 2021, 11, 611676.	2.8	3
36	Appropriate PD-L1 Cutoff Value for Gastric Cancer Immunotherapy: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2021, 11, 646355.	2.8	27

#	Article	IF	CITATIONS
37	Dysregulated KRAS gene-signaling axis and abnormal chromatin remodeling drive therapeutic resistance in heterogeneous-sized circulating tumor cells in gastric cancer patients. Cancer Letters, 2021, 517, 78-87.	7.2	14
38	Redefine Hyperprogressive Disease During Treatment With Immune-Checkpoint Inhibitors in Patients With Gastrointestinal Cancer. Frontiers in Oncology, 2021, 11, 761110.	2.8	5
39	Germline HLA-B evolutionary divergence influences the efficacy of immune checkpoint blockade therapy in gastrointestinal cancer. Genome Medicine, 2021, 13, 175.	8.2	12
40	Tumor copy-number alterations predict response to immune-checkpoint-blockade in gastrointestinal cancer. , 2020, 8, e000374.		43
41	Prediction of immune checkpoint inhibition with immune oncology-related gene expression in gastrointestinal cancer using a machine learning classifier. , 2020, 8, e000631.		22
42	Pyrotinib combined with CDK4/6 inhibitor in HER2â€positive metastatic gastric cancer: A promising strategy from AVATAR mouse to patients. Clinical and Translational Medicine, 2020, 10, e148.	4.0	17
43	The Gut Microbiome Is Associated with Clinical Response to Anti–PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer. Cancer Immunology Research, 2020, 8, 1251-1261.	3.4	155
44	Pathogenic Germline Mutations in Chinese Patients with Gastric Cancer Identified by Next-Generation Sequencing. Oncology, 2020, 98, 583-588.	1.9	7
45	Efficacy and safety of neoadjuvant immunotherapy in patients with microsatellite instability-high gastrointestinal malignancies: A case series. European Journal of Surgical Oncology, 2020, 46, e33-e39.	1.0	24
46	Efficacy, Safety, and Biomarkers of Toripalimab in Patients with Recurrent or Metastatic Neuroendocrine Neoplasms: A Multiple-Center Phase Ib Trial. Clinical Cancer Research, 2020, 26, 2337-2345.	7.0	66
47	Etoposide and cisplatin versus irinotecan and cisplatin as the firstâ€line therapy for patients with advanced, poorly differentiated gastroenteropancreatic neuroendocrine carcinoma: A randomized phase 2 study. Cancer, 2020, 126, 2086-2092.	4.1	37
48	Clinical implications of plasma ctDNA features and dynamics in gastric cancer treated with HER2â€ŧargeted therapies. Clinical and Translational Medicine, 2020, 10, e254.	4.0	23
49	Association of HLA class I genotype with outcomes of gastrointestinal cancer patients with immunotherapy Journal of Clinical Oncology, 2020, 38, e16551-e16551.	1.6	1
50	Use of Radiomics to Predict Response to Immunotherapy of Malignant Tumors of the Digestive System. Medical Science Monitor, 2020, 26, e924671.	1.1	10
51	Current management of chemotherapy-induced neutropenia in adults: key points and new challenges. Cancer Biology and Medicine, 2020, 17, 896-909.	3.0	35
52	Immune checkpoint inhibitors for treatment of advanced gastric or gastroesophageal junction cancer: Current evidence and future perspectives. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2020, 32, 287-302.	2.2	20
53	Change in neutrophial-to-lymphocyte ratio (NLR) in response to immune checkpoint inhibitor for advanced gastric cancer Journal of Clinical Oncology, 2020, 38, 306-306.	1.6	0
54	Effect of TP53 mutation on antitumor immunity and responsiveness to immunotherapy in colorectal cancer Journal of Clinical Oncology, 2020, 38, e16014-e16014.	1.6	0

#	Article	IF	CITATIONS
55	Hyperprogression after immunotherapy in patients with malignant tumors of digestive system. BMC Cancer, 2019, 19, 705.	2.6	27
56	Serological Markers Associated With Response to Immune Checkpoint Blockade in Metastatic Gastrointestinal Tract Cancer. JAMA Network Open, 2019, 2, e197621.	5.9	25
57	Clinicopathologic Characteristics of HER2-positive Metastatic Colorectal Cancer and Detection of HER2 in Plasma Circulating Tumor DNA. Clinical Colorectal Cancer, 2019, 18, 175-182.	2.3	11
58	Nimotuzumab Plus Paclitaxel and Cisplatin as a 1 st -Line Treatment for Esophageal Cancer: Long Term Follow-up of a Phase II Study. Journal of Cancer, 2019, 10, 1409-1416.	2.5	12
59	Hepatoid adenocarcinoma of the stomach: a unique subgroup with distinct clinicopathological and molecular features. Gastric Cancer, 2019, 22, 1183-1192.	5.3	64
60	The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer. Cancer Communications, 2019, 39, 1-31.	9.2	418
61	The ctDNA in peritoneal effusion of advanced gastric cancer for auxiliary diagnosis of peritoneal metastasis Journal of Clinical Oncology, 2019, 37, e15516-e15516.	1.6	1
62	Gls-010, a novel anti-PD-1 mAb in Chinese advanced gastrointestinal tumor: Result of a phase Ib clinical trial Journal of Clinical Oncology, 2019, 37, 125-125.	1.6	5
63	A multi-institutional investigation assessing prevalence of germline genetic alterations in Chinese patients with gastric carcinoma Journal of Clinical Oncology, 2019, 37, e13020-e13020.	1.6	0
64	A multicenter, randomized trial comparing efficacy and safety of paclitaxel/capecitabine and cisplatin/capecitabine in advanced gastric cancer. Gastric Cancer, 2018, 21, 782-791.	5.3	33
65	Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway. Cell Death and Disease, 2018, 9, 123.	6.3	76
66	Survival Benefit of Palliative Local Treatments and Efficacy of Different Pharmacotherapies in Colorectal Cancer With Lung Metastasis: Results From a Large Retrospective Study. Clinical Colorectal Cancer, 2018, 17, e233-e255.	2.3	26
67	Predictive and prognostic value of serum AFP level and its dynamic changes in advanced gastric cancer patients with elevated serum AFP. World Journal of Gastroenterology, 2018, 24, 266-273.	3.3	23
68	Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint. Journal of Experimental and Clinical Cancer Research, 2018, 37, 129.	8.6	37
69	Wee1 Inhibitor AZD1775 Combined with Cisplatin Potentiates Anticancer Activity against Gastric Cancer by Increasing DNA Damage and Cell Apoptosis. BioMed Research International, 2018, 2018, 1-10.	1.9	18
70	Evolutionary Expression of HER2 Conferred by Chromosome Aneuploidy on Circulating Gastric Cancer Cells Contributes to Developing Targeted and Chemotherapeutic Resistance. Clinical Cancer Research, 2018, 24, 5261-5271.	7.0	42
71	Impact of duration of adjuvant chemotherapy in radically resected patients with T4bN1-3M0/TxN3bM0 gastric cancer. World Journal of Gastrointestinal Oncology, 2018, 10, 31-39.	2.0	8
72	Clinical characters and prognostic factors of young female patients (pts) with metastatic gastric adenocarcinoma (GC) Journal of Clinical Oncology, 2018, 36, 133-133.	1.6	0

#	Article	IF	CITATIONS
73	Development of a prognostic index for gastric cancer with liver metastasis at the initial diagnosis: A single center retrospective study Journal of Clinical Oncology, 2018, 36, e16001-e16001.	1.6	0
74	Multimodality Treatment Including Triplet Regimen as First-Line Chemotherapy May Improve Prognosis of Serum AFP-Elevated Gastric Cancer with Liver Metastasis. Gastroenterology Research and Practice, 2017, 2017, 1-9.	1.5	6
75	Nimotuzumab plus paclitaxel and cisplatin as 1st line treatment for unresectable esophageal squamous cell carcinoma: Long term follow-up of survival in a phase II study Journal of Clinical Oncology, 2017, 35, e15573-e15573.	1.6	5
76	Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: A single centre prospective phase II trial. Cancer Science, 2016, 107, 486-490.	3.9	44
77	The anti-HER3 antibody in combination with trastuzumab exerts synergistic antitumor activity in HER2-positive gastric cancer. Cancer Letters, 2016, 380, 20-30.	7.2	20
78	PD-L1 expression is associated with massive lymphocyte infiltration and histology in gastric cancer. Human Pathology, 2016, 55, 182-189.	2.0	58
79	A randomized, multicenter, controlled study to compare perioperative chemotherapy of oxaliplatin combined with TS-1 (SOX) versus SOX or oxaliplatin with capecitabine (XELOX) as post-operative chemotherapy in locally advanced gastric adenocarcinoma with D2 dissection (RESOLVE Trial) lournal of Clinical Oncology, 2016, 34, TPS4136-TPS4136.	1.6	2
80	Aneuploidy of chromosome 8 in circulating tumor cells correlates with prognosis in patients with advanced gastric cancer. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2016, 28, 579-588.	2.2	22
81	HER2 discordance between paired primary gastric cancer and metastasis: a meta-analysis. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2015, 27, 163-71.	2.2	23
82	Combination of microtubule associated protein-tau and β-tubulin III predicts chemosensitivity of paclitaxel in patients with advanced gastric cancer. European Journal of Cancer, 2014, 50, 2328-2335.	2.8	24
83	Clinical significance of phenotyping and karyotyping of circulating tumor cells in patients with advanced gastric cancer. Oncotarget, 2014, 5, 6594-6602.	1.8	69
84	Retrospective analysis of adjuvant chemotherapy for curatively resected gastric cancer. World Journal of Gastroenterology, 2014, 20, 3356.	3.3	1
85	A phase II study of sequential Irinotecan plus cisplatin (IP) and octretide LAR as first-line treatment of metastatic or inoperable poorly differentiated gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC) Journal of Clinical Oncology, 2014, 32, e15156-e15156.	1.6	0
86	Nimotuzumab plus paclitaxel and cisplatin as first-line treatment for esophageal squamous cell cancer: Final results of a single-center prospective clinical trial Journal of Clinical Oncology, 2014, 32, 4070-4070.	1.6	0
87	Management of gastric cancer in Asia: resource-stratified guidelines. Lancet Oncology, The, 2013, 14, e535-e547.	10.7	418
88	Nimotuzumab plus paclitaxel and cisplatin as first-line treatment for esophageal squamous cell cancer: A single center prospective clinical trial Journal of Clinical Oncology, 2013, 31, 4097-4097.	1.6	2
89	Efficacy of paclitaxel plus cisplatin in advanced esophageal squamous cell cancer: Further analysis of single center, prospective study Journal of Clinical Oncology, 2013, 31, e15174-e15174.	1.6	1
90	A FGFR2 inhibitor, Ki23057, enhances the chemosensitivity of drug-resistant gastric cancer cells. Cancer Letters, 2011, 307, 47-52.	7.2	41

#	Article	IF	CITATIONS
91	Retrospective study of cetuximab in combination with chemotherapy for patients with colorectal cancer. Chinese-German Journal of Clinical Oncology, 2008, 7, 400-403.	0.1	1
92	Synergic antiproliferative effect of DNA methyltransferase inhibitor in combination with anticancer drugs in gastric carcinoma. Cancer Science, 2006, 97, 938-944.	3.9	26